Search bioRxivSearch

Biology subjects

Hallak, J.

Publications and source records attributed to Hallak, J..

2 recordsLinked to original sources

Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomised placebo-controlled trial

Major Depressive Disorder affects about 350 million people worldwide, and about one-third of the patients are considered treatment-resistant. Furthermore, available antidepressants take usually two weeks for the onset of their antidepressant effect. Recent open label trials show that psychedelics, such as ayahuasca and psilocybin, hold promise as fast-onset antidepressants. Although promising, these studies were not controlled for the placebo effect. To address this issue, and to further test the antidepressant effects of ayahuasca, we conducted a parallel arm, double-blind randomised placebo-controlled trial, in patients with treatment-resistant major depression. Thirty-five patients with treatment-resistant major depression received a single dose of ayahuasca or placebo. We measured as primary outcome the change in the Hamilton Depression Rating scale (HAM-D) seven days after the dosing session, and as secondary outcomes the changes in Montgomery-[A]sberg Depression Rating Scale (MADRS), and response rates at one day (D1), two days (D2) and seven days (D7) after dosing, and remission rates at D7. This study is registered with http://clinicaltrials.gov (NCT02914769). We observed robust evidence of rapid antidepressant effects of a single dosing session with ayahuasca when compared to placebo. HAM-D scores at D7 were significantly lower in patients treated with ayahuasca than in those treated with placebo (p=0{middle dot}019; Cohens d=0{middle dot}98). MADRS scores were significantly reduced in the ayahuasca group compared to the placebo group at all endpoints (at D1 and D2, p=0{middle dot}04; at D7, p<0{middle dot}0001). Between-group effect sizes increased from D1 to D7 (D1: Cohens d=0{middle dot}84; D2: Cohens d=0{middle dot}84; D7: Cohens d=1{middle dot}49). Response rates were high for both groups at D1 and D2, and were significantly higher in the ayahuasca group only at D7 (64% vs. 27%; OR = 4{middle dot}95; p = 0{middle dot}04; NNT = 2{middle dot}66). Remission rate was not significantly different between groups. Our study provides new evidence of rapid antidepressant effects of ayahuasca for treatment-resistant major depression.

clinical trials

Effects of altered excitation-inhibition balance on decision making in a cortical circuit model

BackgroundDisruption of the synaptic balance between excitation and inhibition (E/I balance) in cortical circuits is a leading hypothesis for pathophysiologies of neuropsychiatric disorders, such as schizophrenia. However, it is poorly understood how synaptic E/I disruptions propagate upward to induce cognitive deficits, including impaired decision making (DM).\n\nMethodsWe investigated how E/I perturbations may impair temporal integration of evidence during perceptual DM in a biophysically-based model of association cortical microcircuits. Using multiple psychophysical task paradigms, we characterized effects of NMDA receptor hypofunction at two key synaptic sites: inhibitory interneurons (elevating E/I ratio, via disinhibition), versus excitatory pyramidal neurons (lowering E/I ratio).\n\nResultsDisruption of E/I balance in either direction can similarly impair DM as assessed by psychometric performance, following inverted-U dependence. Nonetheless, these regimes make dissociable predictions for task paradigms that characterize the time course of evidence accumulation. Under elevated E/I ratio, DM is impulsive: evidence early in time is weighted much more than late evidence. In contrast, under lowered E/I ratio, DM is indecisive: evidence integration and winner-take-all competition between options are weakened. These effects are well captured by an extended drift-diffusion model with self-coupling.\n\nConclusionsOur findings characterize critical roles of cortical E/I balance in cognitive functions, the utility of timing-sensitive psychophysical paradigms, and relationships between circuit and psychological models. The model makes specific predictions for behavior and neural activity that are testable in humans or animals under causal manipulations of E/I balance and in disease states.

neuroscience